WARNING LETTER
ITL Asia Pacific Sdn Bhd
MARCS-CMS 590380 —
September 25, 2019
Delivery Method:
VIA UNITED PARCEL SERVICE
Product:
Medical Devices
Recipient:
Recipient Name
William L. Mobbs
Recipient Title
Executive Chairman
ITL Asia Pacific Sdn Bhd
Plot 17B, Lorong Bemban 2
Bemban Industrial Estate
31000
Batu Gajah
Perak
Malaysia
Issuing Office:
OHT3: Office of Gastrorenal, ObGyn, General Hospital, and Urology Devices, Office of Product Evaluation and Quality
United States
WARNING LETTER
September 25, 2019
Dear Mr. William Mobbs:
During an inspection of your firm located in Batu Gajah, Perak, Malaysia on May 27 through May 30, 2019, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures blood collection devices, specifically the SampLok System with Hinged Lid. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21,
Code of Federal Regulations
(CFR), Part 820.
We received a response from Fong Suit Kook dated June 19, 2019, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:
1. Failure to establish and maintain adequate procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30(a).
Your firm’s Design & Development Control Procedure, Document
(b)(4)
, states that the objective of the procedure is to establish and maintain guidelines for the control of design and development activities. However, you have yet to subject the Class II ITL SampLok Luer Kit through the design control process. Instead, you have established a Design History Compilation for the SampLok Luer Kit to only include Design Inputs, Design Outputs, and Design Changes disregarding Design Plan, Design Reviews, Design Verifications, Design Validation, and Design Transfer.
Additionally, in your Design & Development Control Procedure, Document
(b)(4)
, you include
(b)(4)
regarding “Legacy” Design History Files (DHF). According to this policy, “when legacy documents are revised, they will be brought into compliance with the requirements of this work instruction.” During the investigation you stated no Class II medical device products were subjected through the design control process prior to receiving your ISO 13485 certification in 2013. A review of your Design History Compilation for the ITL SampLok Luer Kit
(b)(4)
revealed that only Design Inputs, Design Outputs, and Design Changes were addressed without consideration of Design Plan, Design Reviews, Design Verifications, Design Validation, and Design Transfer. The revisions for the ITL SampLok Luer Kit were dated 2013 and 2019 respectively. The work instruction clearly includes procedures for Design Planning, Design Input, Design Output, Design Verification, Design Validation, Design Transfer, Design Review, and Design Change.
We reviewed your firm’s response and conclude that it is not adequate. Your response indicates your intent to remediate the SampLok Luer Kit documentation to ensure compliance with
(b)(4)
; however, you did not provide evidence the SampLok Luer Kit, which is a Class II medical device cleared under 510(k) K021941, will actually be subject to the design control process. You claim the abbreviated design control process per
(b)(4)
was utilized for design changes after 2013, and the SampLok Luer Kit was an established product line and it’s DHF was never fully remediated. To correct this issue, you intend to review all existing product lines to confirm a DHF is in place and determine if it needs to be retrospectively created. However, you did not provide any evidence that suggests all devices manufactured at your facility will be subject to the design control process, as articulated by 21 CFR 820.30. Your approach to capture documentation of device design exclusively in your “Design History Compilation” does not address the requirement to establish and maintain appropriate design control processes and procedures as described by 21 CFR 820.30. A Design History Compilation cannot take the place of demonstrating compliance to design controls. In addition, your response does not include evaluation of existing production records to evaluate whether the lack of design controls (particularly design transfer) may have led to the release of nonconforming product.
2. Procedures for corrective and preventive action have not been adequately established as required by 21 CFR 820.100(a).
Your Corrective Action & Preventive Action Procedure, Document
(b)(4)
, states that this procedure applies to the process and product non-conformances in the quality management system implemented within ITLAP. The procedure does not include identification of all the quality data sources to be analyzed or utilization of the appropriate statistical methodology to detect recurring quality problems. The procedure specifies that Corrective Action Requests (CARs) and Non-Conformance Reports (NCRs) are the two quality data sources used to initiate a Corrective and Preventative Action (CAPA). Per
(b)(4)
, CARs may be issued when a “non-conformance of product or process is detected during QC buy-off, customer complaint, deviation of quality system or causes that may originate from paragraph
(b)(4)
”. This includes customer complaints, “failures, malfunctions, and non-conformities in incoming materials, processes, tools, equipment or facilities in which products are processed, stored or handled, including the equipment and systems there in.” However, you neglect to include evaluation or analysis of quality audit reports, service records, or returned product.
We reviewed your firm’s response and conclude that it is not adequate. Your firm promised to review and revise your CAPA procedure to identify all potential sources of quality data to complete proper trending, use statistical methods, and complete an analysis of all sources of quality data to confirm a corrective action is not required. As of the date of this Warning Letter, you have not submit that revised CAPA procedure to the FDA, and you have not provided any further evidence to demonstrate that your firm has implemented corrective actions to address the deficiencies to your CAPA system, identified to you during the May 2019 inspection.
3. A process whose results cannot be fully verified by subsequent inspection and test has not been validated according to established procedures as required by 21 CFR 820.75(a)
Your firm has not validated the mixing process for the
(b)(4)
used in the manufacturing of the SampLok System with Hinged Lid. Specifically, you use a
(b)(4)
with the
(b)(4)
. According to your Parts List, The SampLok System with Hinged Lid requires
(b)(4)
and per
(b)(4)
. However, the process has not been validated to ensure the process is correctly and consistently producing
(b)(4)
or dispensing the correct and consistent amount required for
(b)(4)
.
We reviewed your firm’s response and conclude that it is not adequate. Your firm’s validation procedure
(b)(4)
, does not clearly define the requirement to validate sub-processes and proposed corrective actions to update the procedure to validate sub-processes. Additionally, you intend to conduct a retrospective validation of the
(b)(4)
for the SampLok System with Hinged Lid, update the work instruction for the
(b)(4)
, and review other sub-processes to determine and complete retrospective validation as necessary. You have not provided any evidence to demonstrate that you have implemented any of the proposed corrective actions. In addition, your response does not include a retrospective review of production documentation to evaluate whether the use of an unvalidated mixing process may have resulted in release of nonconforming product.
4. Failure to establish and maintain procedures for validating the device design as established in 21 CFR 820.30(g).
For example,
(b)(4)
of your firm’s 2019, device history records for the manufacturing of the SampLok System with Hinged Lid were reviewed. The rejects from the automated leak test (conducted at
(b)(4)
setting) were retested at a lower pressure
(b)(4)
in order to accept the already rejected products. For example:
-Lot #19D111 – A total of
(b)(4)
units failed the automated leak test (at
(b)(4)
). After retest – Only
(b)(4)
units were rejected (at
(b)(4)
).
-Lot #19D080 – A total of
(b)(4)
units failed the automated leak test (at
(b)(4)
). After retest – Only
(b)(4)
units were rejected (at
(b)(4)
).
In April 2019, your management identified rejected products were being accepted after retesting at a lower pressure and as a result increased the pressure setting of the manual retest to
(b)(4)
; however, acknowledged specifications for leaks were not established in the Device Master Record or the Design History Compilation. Your firm did not perform design validation activities to substantiate that the new pressure setting was appropriate.
We reviewed your firm’s response and concluded it is not adequate. In your response, you state the release criteria for the SampLok System with Hinged Lid is
(b)(4)
and as part of the manufacturing process, an
(b)(4)
is completed. The
(b)(4)
as an early warning for potential leakage that may fail the
(b)(4)
, but this is not reflected in the DHR. Fundamentally, the release criteria of
(b)(4)
is not part of your design inputs because your Quality System lacks the appropriate design controls as identified in Observation 1. As related to design validation, you have not provided evidence to demonstrate that a validation procedure has been established to support the leak tests at
(b)(4)
or explain the reasoning behind the early warning test at
(b)(4)
if the acceptance criteria is at
(b)(4)
. Additionally, you proposed to review customer complaints and risk assessments to confirm the current QC release criteria is adequate, complete a correlation between the in-line leak test and final leak test, and update your work instructions; however, you have not provided evidence your firm has implemented these proposed corrective actions.
5. Failure to adequately ensure that when an investigation is made under 21 CFR 820.198, a record of the investigation shall be maintained by the formally designated unit identified in 21 CFR 820.198(a), as required by 21 CFR 820.198(e).
A review of your firm’s complaints from 2017 to 2019, (with a total of 8 closed complaints) revealed that you failed to document the results of the investigations, whether the corrective action was taken, or verification of the effectiveness of the corrective actions. Per your Handling of Customer Complaints Procedure - Doc
(b)(4)
, for a complaint which is determined that a corrective action is necessary, the team will determine the root cause, identify, implement, verify corrective actions, and determine effectiveness of corrective actions. Complaint records will include customer complaint notification record, complaint log, response letter, investigation report, all other complaint relevant records, and raw testing or evaluation data. Your firm failed to have these records on file.
We reviewed your firm’s response and concluded it is not adequate. Your firm stated
(b)(4)
does not clearly define the responsibilities for receiving, reviewing, and evaluating customer complaints and to correct this, you propose to review and revise the procedure to ensure regulatory requirement compliance. Additionally, you intend to investigate the listed complaints and retroactively write up action plans and follow up until closure
(b)(4)
, and
(b)(4)
to add additional information. Lastly, you plan to review all customer complaints from
(b)(4)
, for completeness of documentation. Your firm’s response does not explain the lack of adherence to your own procedures set forth in
(b)(4)
. Your firm has not provided evidence you have implemented these proposed corrective actions.
Our inspection also revealed that your firm’s devices are misbranded under Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 - Medical Device Reporting. Significant deviations include, but are not limited to:
Failure to adequately develop, maintain and implement written MDR procedures, as required by 21 CFR 803.17. For example, during the inspection, your firm provided the investigator with a document identified as your firm’s MDR procedure, titled “Medical Device Reporting”,
(b)(4)
, we determined that it does not contain information that would indicate that it was an MDR procedure created in accordance with the requirements in 21 CFR 803.17. For example, your procedure did not include a standardized system to effectively identify, communicate, and evaluate events that may require a MDR and did not comply with documentation and record keeping requirements.
We reviewed your firm’s response and conclude that it is not adequate. In the response, your firm promised to revise its procedure
(b)(4)
to assure compliance to all regulatory and management systems and provide training for relevant employees. However, your firm did not provide evidence of implementation of its systemic corrective action, including a revised version of its MDR procedure and evidence of employee training.
Given the serious nature of the violations of the Act, blood collection devices, specifically the SampLok System with Hinged Lid manufactured by your firm are subject to refusal of admission under section 801(a) of the Act, 21 U.S.C. § 381(a), in that they appear to be adulterated. As a result, FDA is taking steps to refuse entry of these devices into the United States, known as “detention without physical examination,” until these violations are corrected. In order to remove the devices from detention, your firm should provide a written response to this Warning Letter as described below and correct the violations described in this letter. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and/or corrective actions have been made.
Also, U.S. Federal Agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, premarket approval applications for Class III devices to which the Quality System regulation deviations are reasonably related will not be approved until the violations have been corrected.
Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and/or corrective actions have been made.
Your firm’s response should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Inspections and Regulatory Audits Team, White Oak Building 66, Rm 3540, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS Case# 590380 when replying. If you have any questions about the contents of this letter, please contact: CDR Nikhil Thakur at 301-796-5536.
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.
Sincerely yours,
/S/
Benjamin R. Fisher
Director
OHT 3: Office of Gastrorenal, OB/GYN, General
Hospital, and Urology Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
CC:
US Agent: Susan Finneran
Regulatory Compliance Experts, Inc.
Phone: 781-664-0074
Email address: Sue.Finneran@Gmail.com
Content current as of:
03/03/2020
Regulated Product(s)
Medical Devices